Bristol Myers Squibb / BMS

Bristol Myers Squibb / BMS appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as the earlier PD-1 mover whose lead was later overtaken by [[Merck|默沙东]]’s [[Keytruda|K药]] in the source’s account. The episode uses this comparison to argue that clinical-development strategy and indication expansion can matter as much as first entry.

Its source role is a cautionary one. Platform class success does not guarantee company-level dominance, and early technical position can be lost if another company executes better clinically and commercially.

Connections

• PD-1 Market Saturation - crowded market context.
• Merck / 默沙东 and Keytruda / K药 - comparator company and product.
• Multinational Pharma Patent-Cliff Anxiety - patent and pipeline-pressure context.